Timing is everything
for some patients

Accelerate PhenoTest™ BC Kit –

A recent customer study showed identification and susceptibility results with MICs an average of 42 hours faster than their standard of care.*

*Data on file, manuscript in preparation
90 min
identification
7 hr
susceptibility
 

Admitted Sunday.
MIC results Monday.

The Accelerate PhenoTest™ BC Kit makes earlier optimal therapy possible by providing answers, directly from positive blood cultures, that drive treatment decisions 1-2 days faster than current methods allow today.

Earlier optimal therapy can lead to reduced cost of patient care, fewer adverse incidents, lower rate of resistance, and better clinical outcomes.

Clinical relevancy

Timely escalation to effective therapy reduces mortality

Impact of Time to Definitive Therapy on Mortality4
Empiric therapy may not be adequate in up to 25% of patients with bloodstream infections (BSIs).4 Shortening the time horizon from empiric to optimal therapy requires susceptibility results with the MIC for 52% of patients with BSIs.5

4 Retamar et al. Antimicrob Agents Chemother. 2012 Jan;56(1):472-8
5 Huang et al. Clin Infect Dis. 2013 Nov;57(9):1237-45

Timely escalation to effective therapy reduces hospital length of stay

Impact of Effectiveness of Antibiotic on Hospital Length of Stay (Gram-negative sepsis)6
Reducing hospital length of stay (LOS) by two days reduces broad spectrum antibiotic exposure that may increase the risk of HAIs, C. difficile infection, and increase risk of community-acquired resistance. It also substantially reduces cost of care.

6 Shorr et al, Crit Care Med 2011. Jan; 39(1): 46-51

De-escalation can improve patient outcomes

% CDI Incidence by Number of Simultaneous Drug Classes Administered

Reducing the time frame from empiric broad-spectrum antibiotic coverage to optimal therapy has been shown to dramatically reduce the incidence of C. difficile in patients with BSIs.7

Reporting antimicrobial susceptibility results 1-2 days faster gives clinicians the data required to move to targeted optimal therapy faster.

7 Tartof et al, 2015. Infect. Control Hosp. Epidemiol. 2015;36(12) :1409–1416

Sensible economics

Potential economic impact across a hospital system serviced by a centralized microbiology lab*
$4.8k
net savings per patient tested
1.7k
fewer ICU days
each year
$10.8m
net financial impact to hospital system
*Estimated healthcare outcome and economic impact based on model of first full year of testing on positive blood culture samples.
Walk me through this

Gram-Positive

Identification
Ampicilin
Ceftaroline
Doxycycline
Erythromycin
Trimethroprim-
Sulfamethoxazole
Daptomycin
Linezolid
Vancomycin
MRSA
(Cefoxitin)
MLSb
(Erythromycin-
Clindamycin)
S. aureus
S. lugdunensis
CoNS spp.
E. faecalis
E. faecium
Streptococcus spp.
S. agalactiae
Resistance
Phenotypes
S. aureus S. lugdunensis CoNS spp. E. faecalis E. faecium Streptococcus spp. S. agalactiae
Identification
Ampicilin
Ceftaroline
Doxycycline
Erythromycin
Trimethroprim-Sulfamethoxazole
Daptomycin
Linezolid
Vancomycin
MRSA (Cefoxitin)
Resistance Phenotypes
MLSb (Erythromycin-Clindamycin)

CE Marked for in-vitro diagnostic use.
See instructions for use for additional detail.

Gram-Negative

Identification
Ampicillin
Amox-Clav
Ampicillin-
Sulbactam
Piperacillin-
Tazobactam
Cefazolin
Cefuroxime
Ceftriaxone
Ceftazidime
Cefepime
Aztreonam
Ertapenem
Meropenem
Gentamicin
Tobramycin
Amikacin
Trimethroprim-
Sulfamethoxazole
Ciprofloxacin
Minocycline
Colistin
AmpC screen
(Cefoxitin)
E. coli
Klebsiella spp.
Enterobacter spp.
Proteus spp.
Citrobacter spp.
S. marcescens
P. aeruginosa
A. baumannii
E. coli Klebsiella spp. Enterobacter spp. Proteus spp. Citrobacter spp. S. marcescens P. aeruginosa A. baumannii
Identification
Ampicillin
Amox-Clav
Ampicillin-
Sulbactam
Piperacillin-
Tazobactam
Cefazolin
Cefuroxime
Ceftriaxone
Ceftazidime
Cefepime
Aztreonam
Ertapenem
Meropenem
Gentamicin
Tobramycin
Amikacin
Trimethroprim-
Sulfamethoxazole
Ciprofloxacin
Minocycline
Colistin
AmpC screen
(Cefoxitin)

Yeast

Identification
Candida albicans
Candida glabrata
 

Klebsiella spp.
K. oxytoca
K. pneumoniae

Enterobacter spp.
E. cloacae
E. aerogenes

Proteus spp.
P. mirabilis
P. vulgaris

Citrobacter spp.
C. freundii
C. koseri

Coagulase-Negative
Staphylococcus spp.

S. capitis
S. epidermidis
S. haemolyticus
S. hominis
S. lugdunensis
S. warneri

Streptococcus spp.
S. agalactiae
S. gallolyticus
S. mitis
S. oralis
S. pneumoniae

Specifications

48-channel disposable test cassette
Reagent cartridge
Sample vial

The Accelerate PhenoTest™ BC kit is run directly with positive blood culture samples.
Store BC kits at 2-8°C. Do not store at room temperature.

1 Kit

Dimensions:
2.5 h x 8 w 12 l in
6.2 h x 20 w x 30 l cm

Weight:
2.1 lb
950 g

Storage: 2.8°C

5 Pack, including packaging

Dimensions:
13 h x 12.5 w x 13 l in
33 h x 32.5 w x 33 l cm

Weight:
33 lb
15 kg

Publications

Feb 02, 2018

Multicenter Evaluation of the Accelerate PhenoTest™ BC Kit for Rapid Identification and Phenotypic Antimicrobial Susceptibility Testing Using Morphokinetic Cellular Analysis.

Oct 20, 2017

Analytical Performance Characteristics of the Accelerate PhenoTM system for Pathogen Identification and Susceptibility Testing for Gram-negative Bacteremia and Candidemia
IDWeek 2017

Oct 20, 2017

Clinical Impact of Expedited Pathogen Identification and Susceptibility Testing for Gram-negative Bacteremia and Candidemia Using the Accelerate PhenoTM system
IDWeek 2017

Oct 20, 2017

Accelerating Time to Pathogen-adapted Antibiotic Treatment through Culture- independent Antimicrobial Susceptibility Testing in Patients suffering from Sepsis
IDWeek 2017

See all publications